Charité - Universitätsmedizin Berlin

Mobile Apps in Rheumatology: Review and Analysis Using the Mobile App Rating Scale (MARS) (2019) Knitza J, Tascilar K, Messner EM, Meyer M, Vossen D, Pulla A, Bosch P, et al. Conference contribution Facilitated Data Relay and Effects on Treatment of Severe Aortic Stenosis in Europe (2019) Steeds RP, Lutz M, Thambyrajah J, Serra A, Schulz E, Maly J, Aiello M, et al. Journal article The impact of chloride secretion on the progression of polycystic kidney disease (2019) Kraus A, Faria D, Schley G, Schoedel J, Grampp S, Peters DJ, Schreiber R, et al. Conference contribution The polyamine system in acute and chronic kidney injury (2019) Sieckmann T, Faehling M, Ashraf MI, Schley G, Vigolo E, Rosenberger C, Aigner F, et al. Conference contribution Chemotherapy (CT)-induced anaemia in patients (pts) treated with dose-dense regimen: Results of the prospectively randomised anaemia substudy from the neoadjuvant GeparOcto study (2019) Tesch H, Loibl S, Kast K, Jackisch C, Moebus V, Buchen S, Untch M, et al. Conference contribution PRECYCLE Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy (2019) Degenhardt T, Fasching P, Lueftner D, Mueller V, Thomssen C, Schem C, Witzel I, et al. Conference contribution Risk factors for locoregional recurrence (LRR) after neoadjuvant chemotherapy: Pooled analysis of prospective neoadjuvant breast cancer (BC) trials (2019) Werutsky G, Untch M, Hanusch C, Fasching P, Blohmer JU, Seiler S, Denkert C, et al. Conference contribution Utility of the CPS plus EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy (2019) Marme F, Solbach C, Michel L, Fasching P, Schneeweiss A, Blohmer JU, Rezai M, et al. Conference contribution A phase I dose-escalation and expansion trial of intratumorally administered CV8102, alone and in combination with anti-PD-1 in patients with advanced solid tumours (2019) Krauss J, Eigentler T, Schreiber J, Weishaupt C, Terheyden P, Heinzerling L, Mohr P, et al. Conference contribution Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen (2019) Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution